Triomics Secures $22 Million In Series B Funding Led By Battery Ventures

Triomics, a NYC-based oncology AI company, has raised $22 million in Series B funding, bringing its total funding to over $36 million. The investment will aid in expanding adoption across health systems, oncology networks, and life sciences organizations.

Summary of transaction details:

• Deal Type: Series B
• Transaction Amount: $22,000,000
• Founders: Sarim Khan & Hrituraj Singh
• Headquarters: New York
• Notable Investors: Battery Ventures, Nexus Venture Partners, Lightspeed, Y Combinator, Oncology Ventures, Precision Health Informatics

Led by CEO Sarim Khan and CTO Hrituraj Singh, Triomics develops infrastructure that transforms longitudinal cancer records into structured, explainable intelligence. This technology supports various applications such as trial matching, pre-visit chart preparation, and oncology data abstraction.